RSV Vaccine Eligibility Expands
Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.
-
By
-
Kathryn Wighton
-
March 13, 2026
-
Clinical Scorecard: RSV Vaccine Eligibility Expands
At a Glance
| Category | Detail |
|---|
| Condition | Respiratory Syncytial Virus (RSV) Infection |
| Key Mechanisms | Vaccine contains recombinant RSV glycoprotein F stabilized in the prefusion conformation with AS01E adjuvant system. |
| Target Population | Adults aged 18 to 49 years at increased risk for RSV-related lower respiratory tract disease. |
| Care Setting | Outpatient and emergency department settings. |
Key Highlights
- FDA expanded Arexvy vaccine indication to adults aged 18-49 at increased risk.
- Approximately 21 million adults under 50 have risk factors for severe RSV.
- RSV causes an estimated 17,000 hospitalizations annually in adults aged 18-49.
Guideline-Based Recommendations
Diagnosis
- Assess risk factors for severe RSV infection in adults.
Management
- Administer Arexvy vaccine to eligible adults aged 18-49 at increased risk.
Monitoring & Follow-up
- Monitor for adverse events post-vaccination, particularly within 4 days.
Risks
- Adverse events may include injection site pain, fatigue, myalgia, headache, and arthralgia.
Patient & Prescribing Data
Adults aged 18 to 49 years with chronic medical conditions.
Vaccine efficacy demonstrated in phase 3 trials; safety profile consistent with earlier studies.
Clinical Best Practices
- Evaluate patients for chronic conditions that increase RSV risk.
- Educate patients on the importance of vaccination against RSV.
References
